JP Morgan raises Mirum Pharmaceuticals price target to $125

0 min read     Updated on 02 Jul 2026, 10:23 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

JP Morgan analyst Jessica Fye maintained an Overweight rating on Mirum Pharmaceuticals and raised the price target to $125 from $115, signaling confidence in the stock's future performance.

powered bylight_fuzz_icon
44556782

*this image is generated using AI for illustrative purposes only.

JP Morgan analyst Jessica Fye maintained an Overweight rating on Mirum Pharmaceuticals and raised the price target to $125 from $115. The adjustment reflects a positive outlook on the company's stock performance potential.

Rating and Price Target

The brokerage firm continues to endorse the stock with an Overweight rating, suggesting expectations for the shares to outperform the market average. The revised price target indicates an upside from the previous level of $115.

Metric Value
Rating Overweight
New Price Target $125
Previous Price Target $115

What specific factors drove the decision to raise the price target?

How might Mirum's upcoming product pipeline influence future stock performance?

What are the potential risks that could hinder the stock from reaching the new price target?

like17
dislike

Citizens raises Mirum Pharmaceuticals price target to $146

0 min read     Updated on 15 Jun 2026, 09:04 PM
scanx
Reviewed by
Radhika SScanX News Team
AI Summary

Citizens analyst Jonathan Wolleben maintains a Market Outperform rating on Mirum Pharmaceuticals and raises the price target to $146 from $140.

powered bylight_fuzz_icon
43083259

*this image is generated using AI for illustrative purposes only.

Citizens analyst Jonathan Wolleben has maintained a Market Outperform rating for Mirum Pharmaceuticals while raising the stock's price target. The new target of $146 represents an increase from the previous estimate of $140.

Rating and Price Action

The analyst's decision to upgrade the price target reflects a positive outlook on the company's performance. Mirum Pharmaceuticals continues to trade on the NASDAQ under the ticker symbol MIRM.

Metric Value
Rating Market Outperform
Previous Price Target $140
New Price Target $146

What specific factors drove the $6 increase in the price target?

How might this rating upgrade impact Mirum's stock performance in the near term?

What upcoming catalysts could further influence Mirum's stock valuation?

like16
dislike

More News on Mirum Pharmaceuticals Inc